News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Seth A. Wander

Articles by Seth A. Wander

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

ByDavid J. Portman,Matthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Guiseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Sarah Sammons, MD,Sherry Shen, MD,Christ Twelves,Paul V. Plourde,Senthil Damodaran

April 27th 2025

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

ByPooja Advani, MBBS, MD,Sofia Braga,Adam M. Brufsky, MD, PhD,Karthik V. Giridhar,Erica L. Mayer, MD, MPH,Kelly E. McCann,Ruth M. O’Regan,Cristina Saura,Seth A. Wander,Georg F. Bischof,Beth H. Lowenthal,Judith D. Bebchuk,Lisa D. Eli,Brian G. Barnett,Joyce A. O’Shaughnessy,Tufia C. Haddad

April 11th 2025

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

© 2025 MJH Life Sciences^®

All rights reserved.